What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. (17th May 2018)

• Record Type: Journal Article
• Authors: Vialaret, Jérôme; Broutin, Sophie; Pugnier, Célia; Santelé, Sophie; Jaffuel, Aurore; Barnes, Alan; Tiers, Laurent; Pelletier, Laurent; Lehmann, Sylvain; Paci, Angelo; Hirtz, Christophe
• Is Part Of: Bioanalysis. Volume 10:Number 10(2018)
• Page Start: 723
• Page End: 735
• Publication Date: 2018-05-17
• Subjects: automation -- bevacizumab -- MS -- nSMOL -- protein-A purification -- therapeutic drug monitoring; Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio-2018-0027
• Languages: English
• ISSNs: 1757-6180

Abstract

Aim: Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies.Materials & methods: In this work, we developed a workflow based on an automated protein-A capture and LC–MS/MS analysis to quantify bevacizumab on patient serum during treatment. This analytical approach was fully validated and compared with a commercially available Monoclonal antibody-based treatment preparation (nanosurface and molecular-orientation limited kit).Results: The analytical comparison of the two preparative workflows based on protein-A capture gave similar results with a better lower limit of quantification for the nanosurface and molecular-orientation limited kit (0.26986 vs 1.9565 μg/ml).Conclusion: LC–MS/MS has clear advantages compared with ELISA when considering method development time, multiplexing capacities and absolute quantification with internal standardization. Graphical abstract: